P1.28. Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Hyung-Joo Oh
Meta Tag
Speaker Hyung-Joo Oh
Topic Local-Regional NSCLC
durvalumab consolidation
unresectable stage III non-small cell lung cancer
real-world progression-free survival
overall survival
objective response rate
adverse events
PD-L1 expression
radiation pneumonitis
immune-related adverse events
Powered By